Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in:

Open Access 01-12-2024 | Interferon | Review

The challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor

Authors: Manar Mikhail Atyah, Yongliang Sun, Zhiying Yang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

Background

Hepatic epithelioid hemangioendothelioma (HEHE) is a malignant vascular tumor known for its rarity. The different types of this hepatic tumor (single, multiple-nodular or diffused) indicate different prognosis and treatment plans. However, the heterogenic clinical manifestation creates a dilemma and a wide range of challenges when attending to HEHE patients. This review addresses the unique profile and clinical challenges that complicate the diagnosis and treatment of HEHE while focusing on current therapeutic strategies and their limitations.

Main text

The unclear etiology is a challenging feature of HEHE. The exact involvement of potential risk factors and mechanism of development are still undefined. Relevant genetic alterations like WWTR1–CAMTA1 fusion have been investigated; however, they are only applicable as diagnostic markers and their influence on therapeutic efficacy is largely unknown. Other characteristics include asymptomatic manifestation, lack of unique hepatic functional alterations, high rates of misdiagnosis and late-stage identification when metastases already exist. Currently, tissue biopsy is the main tool to establish a definite diagnosis but is challenged with the limited awareness to suspect HEHE at early stages and the lack of relevant guidelines due to the rarity and the insufficiency of relevant research. The absence of treatment guidelines is the greatest challenge of HEHE. Generally, Surgical approaches are recommended due to the benefits of prolonged survival and enhanced prognosis. Nonetheless, only a minority of patients are eligible for resections while liver transplants are faced with severe insufficiency of donor organs and long wait-lists. On the other hand, a variety of non-surgical treatments (like anti-angiogenic agents, interferon alpha-2B and sirolimus) are presented with a promising potential. However, relevant studies are challenged with limited sample-sizes and lack of prospective designs.

Conclusion

Regardless to decades passing since its discovery, HEHE still creates a dilemma due to its challenging clinical profile and lack of treatment guidelines. Raising awareness of HEHE in clinical practices improves the ability to diagnose this rare tumor at early stages and develop stronger research strategies and treatment guidelines to regulate the medical care provided to HEHE patients.
Appendix
Available only for authorised users
Literature
1.
Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev. 2014;8(2):259.PubMedPubMedCentral
2.
Studer LL, Selby DM. Hepatic Epithelioid Hemangioendothelioma. Arch Pathol Lab Med. 2018;142(2):263–7.PubMedCrossRef
3.
Murali R, Zarka MA, Ocal IT, Tazelaar HD. Cytologic features of epithelioid hemangioendothelioma. Am J Clin Pathol. 2011;136(5):739–46.PubMedCrossRef
4.
Lau K, Massad M, Pollak C, Rubin C, Yeh J, Wang J, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140(5):1312–8.PubMedCrossRef
5.
Rosenberg A, Agulnik M. Epithelioid Hemangioendothelioma: update on diagnosis and treatment. Curr Treat Options Oncol. 2018;19(4):19.PubMedCrossRef
6.
Elleuch N, Dahmani W, Aida Ben S, Jaziri H, Aya H, Ksiaa M, et al. Hepatic epithelioid hemangioendothelioma: a misdiagnosed rare liver tumor. Presse Med. 2018;47(2):182–5.PubMedCrossRef
7.
Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107(9):2108–21.PubMedCrossRef
8.
Torres LR, Timbó LS, Ribeiro CM, Galvão Filho MM, Verrastro CG, D’Ippolito G. Multifocal and metastatic hepatic hemangioendothelioma: case report and literature review. Radiol Bras. 2014 May-Jun;47(3):194–6.
9.
Kou K, Chen YG, Zhou JP, Sun XD, Sun DW, Li SX, et al. Hepatic epithelioid hemangioendothelioma: update on diagnosis and therapy. World J Clin Cases. 2020;8(18):3978–87.PubMedPubMedCentralCrossRef
10.
Llueca A, Piquer D, Maazouzi Y, Medina C, Delgado K, Serra A, et al. Hepatic epithelioid hemangioendothelioma: a great mimicker. Int J Surg Case Rep. 2018;53:25–8.PubMedPubMedCentralCrossRef
11.
Virarkar M, Saleh M, Diab R, Taggart M, Bhargava P, Bhosale P. Hepatic hemangioendothelioma: an update. World J Gastrointest Oncol. 2020;12(3):248–66.PubMedPubMedCentralCrossRef
12.
Läuffer JM, Zimmermann A, Krähenbühl L, Triller J, Baer HU. Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. Cancer. 1996;78(11):2318–27.PubMedCrossRef
13.
Duletić-Nacinović A, Grohovac D, Dobrila-Dintinjana R, Brncić N, Jonjić N. Aggressive multifocal form of epithelioid hemangioendothelioma–case report. Coll Antropol. 2011;35(Suppl 2):289–93.PubMed
14.
Bellmunt J, Allende E, Navarro M, Morales S, Sans M, Jolis L, et al. Epithelioid hemangioendothelioma of the liver with myocardial metastases. Jpn J Clin Oncol. 1989;19(2):153–8.PubMed
15.
Bisbee CA 2nd, Burstiner L, Natcheva H. Hepatic Epithelioid Hemangioendothelioma with Unique Metastasis to the Superior Vena Cava Found on CT Imaging: a Case Study. Cureus. 2022;14(6):e26155.
16.
Gurung S, Fu H, Zhang WW, Gu YH. Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report. Int J Clin Exp Pathol. 2015;8(5):5883–9.PubMedPubMedCentral
17.
Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999;85(3):562–82.PubMedCrossRef
18.
Kawka M, Mak S, Qiu S, Gall TMH, Jiao LR. Hepatic epithelioid hemangioendothelioma (HEHE)-rare vascular malignancy mimicking cholangiocarcinoma: a case report. Transl Gastroenterol Hepatol. 2022;7:42.PubMedPubMedCentralCrossRef
19.
Mucha K, Foroncewicz B, Zieniewicz K, Nyckowski P, Krawczyk M, Cyganek A et al. Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years’ observation. Transplant Proc. 2006 Jan-Feb;38(1):231-3.
20.
Zhou L, Cui MY, Xiong J, Dong Z, Luo Y, Xiao H, et al. Spectrum of appearances on CT and MRI of hepatic epithelioid hemangioendothelioma. BMC Gastroenterol. 2015;15:69.PubMedPubMedCentralCrossRef
21.
Liu X, Yu H, Zhang Z, Si S, Huang J, Tan H, et al. MRI appearances of hepatic epithelioid hemangioendothelioma: a retrospective study of 57 patients. Insights Imaging. 2022;13(1):65.PubMedPubMedCentralCrossRef
22.
Emamaullee JA, Edgar R, Toso C, Thiesen A, Bain V, Bigam D, et al. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transpl. 2010;16(2):191–7.PubMedCrossRef
23.
Deng Y, Zhou Y, Cheng N. Laparoscopic liver biopsy in the diagnosis of hepatic epithelioid hemangioendothelioma: a case report. Oncol Lett. 2014;8(3):1317–9.PubMedPubMedCentralCrossRef
24.
Venkatesh SK, Chandan V, Roberts LR. Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol. 2014;12(9):1414–29.PubMedCrossRef
25.
Zhang L, Zhou Y, Zhang J. An incidental hepatic epithelioid hemangioendothelioma in a patient with chronic hepatitis: lost in the maze. Rev Esp Enferm Dig. 2022;114(2):125–6.PubMed
26.
Baron PW, Amankonah T, Cubas RF, Kore AH, Elihu A, de Vera ME, et al. Diffuse hepatic epithelioid hemangioendothelioma developed in a patient with hepatitis C cirrhosis. Case Rep Transpl. 2014;2014:694903.
27.
Kanno H, Sato T, Midorikawa R, Kojima S, Fukutomi S, Goto Y, et al. Hepatic epithelioid Hemangioendothelioma presenting synchronously with Hepatocellular Carcinoma. Case Rep Gastroenterol. 2021;15(1):344–51.PubMedPubMedCentralCrossRef
28.
Athanasopoulos PG, Hadjittofi C, Luong TV, O’Beirne J, Sharma D. Synchronous hepatic Epithelioid Hemangioendothelioma and Hepatocellular Carcinoma: First Case Report in the Literature and challenges. Med (Baltim). 2015;94(34):e1377.CrossRef
29.
Dean PJ, Haggitt RC, O’Hara CJ. Malignant epithelioid hemangioendothelioma of the liver in young women. Relationship to oral contraceptive use. Am J Surg Pathol. 1985;9(10):695–704.PubMedCrossRef
30.
Kelleher MB, Iwatsuki S, Sheahan DG. Epithelioid hemangioendothelioma of liver. Clinicopathological correlation of 10 cases treated by orthotopic liver transplantation. Am J Surg Pathol. 1989;13(12):999–1008.PubMedCrossRef
31.
Singhal S, Jain S, Singla M, Pippal RB, Gondal R, Agarwal A, et al. Multifocal epitheloid hemangioendothelioma of liver after long-term oral contraceptive use–a case report and discussion of management difficulties encountered. J Gastrointest Cancer. 2009;40(1–2):59–63.PubMedCrossRef
32.
Gelin M, Van de Stadt J, Rickaert F, De Prez C, Levarlet M, Adler M, et al. Epithelioid hemangioendothelioma of the liver following contact with vinyl chloride. Recurrence after orthotopic liver transplantation. J Hepatol. 1989;8(1):99–106.PubMedCrossRef
33.
Shin MS, Carpenter JT Jr, Ho KJ. Epithelioid hemangioendothelioma: CT manifestations and possible linkage to vinyl chloride exposure. J Comput Assist Tomogr. 1991 May-Jun;15(3):505–7.
34.
Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and bone. Cancer. 2014;120(12):1763–74.PubMedCrossRef
35.
Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82.PubMedCrossRef
36.
Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–53.PubMedPubMedCentralCrossRef
37.
Doyle LA, Fletcher CD, Hornick JL. Nuclear expression of CAMTA1 distinguishes Epithelioid Hemangioendothelioma from histologic mimics. Am J Surg Pathol. 2016;40(1):94–102.PubMedCrossRef
38.
Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, et al. The Hippo pathway in biological control and cancer development. J Cell Physiol. 2011;226(4):928–39.PubMedCrossRef
39.
Errani C, Sung YS, Zhang L, Healey JH, Antonescu CR. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 2012 Jan-Feb;205(1–2):12–7.
40.
Seavey CN, Pobbati AV, Hallett A, Ma S, Reynolds JP, Kanai R, et al. WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis. Genes Dev. 2021;35(7–8):512–27.PubMedPubMedCentralCrossRef
41.
Lotfalla MM, Folpe AL, Fritchie KJ, Greipp PT, Galliano GG, Halling KC, et al. Hepatic YAP1-TFE3 rearranged Epithelioid Hemangioendothelioma. Case Rep Gastrointest Med. 2019;2019:7530845.PubMedPubMedCentral
42.
Bourgeau M, Martinez A, Deeb KK, Reid MD, Lewis M, Point du Jour KS, et al. Cytologic features of hepatic YAP1-TFE3 rearranged epithelioid hemangioendothelioma. Diagn Cytopathol. 2021;49(12):E447–52.PubMedCrossRef
43.
Morishita A, Iwama H, Yoneyama H, Sakamoto T, Fujita K, Nomura T, et al. MicroRNA profile of hepatic epithelioid hemangioendothelioma: a case report. Oncol Lett. 2017;13(3):1655–9.PubMedPubMedCentralCrossRef
44.
Giovanardi F, Larghi Laureiro Z, Meo GA, Hassan R, Lai Q. The challenging surgical management of hepatic epithelioid hemangioendothelioma: a narrative review. Chin Clin Oncol. 2022;11(4):27.PubMedCrossRef
45.
Chahrour MA, Khachfe HH, Habib JR, El-Asmar R, Saifi O, Jamali FR. Treatment and prognosis of Hepatic Epithelioid Hemangioendothelioma: a SEER database analysis. World J Surg. 2021;45(9):2886–94.PubMedCrossRef
46.
Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, et al. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford). 2010;12(8):546–53.
47.
Galvão FH, Bakonyi-Neto A, Machado MA, Farias AQ, Mello ES, Diz ME, Machado MC. Interferon alpha-2B and liver resection to treat multifocal hepatic epithelioid hemangioendothelioma: a relevant approach to avoid liver transplantation. Transpl Proc. 2005;37(10):4354–8.CrossRef
48.
Imanishi H, Kawata M, Yanagihara M, Nakayama N, Sato T, Furukawa Y, et al. Epithelioid hemangioendothelioma of the liver associated with thrombocytopenia and coagulopathy. Hepatogastroenterology. 2002 Nov-Dec;49(48):1673–5.
49.
Oshima N, Terajima H, Hosotani R. Surgical Therapy for a Solitary form of hepatic epithelioid hemangioendothelioma: a long-term survival case. Case Rep Gastroenterol. 2009;3(2):214–21.PubMedPubMedCentralCrossRef
50.
Wang JK, Wu ZR, Su F, Ma WJ, Hu HJ, Li FY. Resectable single hepatic Epithelioid Hemangioendothelioma in the left lobe of the liver: a Case Report. Open Med (Wars). 2018;13:456–9.PubMedCrossRef
51.
Remiszewski P, Szczerba E, Kalinowski P, Gierej B, Dudek K, Grodzicki M, et al. Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation. World J Gastroenterol. 2014;20(32):11333–9.PubMedPubMedCentralCrossRef
52.
Madariaga JR, Marino IR, Karavias DD, Nalesnik MA, Doyle HR, Iwatsuki S, et al. Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol. 1995;2(6):483–7.PubMedPubMedCentralCrossRef
53.
Tan Y, Yang X, Dong C, Xiao Z, Zhang H, Wang Y. Diffuse hepatic epithelioid hemangioendothelioma with multiple splenic metastasis and delayed multifocal bone metastasis after liver transplantation on FDG PET/CT images: a case report. Med (Baltim). 2018;97(22):e10728.CrossRef
54.
Brahmbhatt M, Prenner S, Bittermann T. Liver transplantation for hepatic epithelioid hemangioendothelioma is facilitated by exception points with acceptable long-term outcomes. Transplantation. 2020;104(6):1187–92.PubMedCrossRef
55.
Thomas RM, Aloia TA, Truty MJ, Tseng WH, Choi EA, Curley SA, et al. Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. HPB (Oxford). 2014;16(7):677–85.PubMedCrossRef
56.
Thin LW, Wong DD, De Boer BW, Ferguson JM, Adams L, Macquillan G, et al. Hepatic epithelioid haemangioendothelioma: challenges in diagnosis and management. Intern Med J. 2010;40(10):710–5.PubMedCrossRef
57.
Komatsu Y, Koizumi T, Yasuo M, Urushihata K, Yamamoto H, Hanaoka M, et al. Malignant hepatic epithelioid hemangioendothelioma with rapid progression and fatal outcome. Intern Med. 2010;49(12):1149–53.PubMedCrossRef
58.
Mo WF, Tong YL. Hepatic epithelioid hemangioendothelioma after thirteen years’ follow-up: a case report and review of literature. World J Clin Cases. 2022;10(18):6119–27.PubMedPubMedCentralCrossRef
59.
Afrit M, Nasri M, Labidi S, Mejri N, El Benna H, Boussen H. Aggressive primary hepatic epithelioid hemangioendothelioma: a case report and literature review. Cancer Biol Med. 2017;14(2):187–90.PubMedPubMedCentralCrossRef
60.
61.
62.
63.
Salech F, Valderrama S, Nervi B, Rodriguez JC, Oksenberg D, Koch A, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann Hepatol. 2011 Jan-Mar;10(1):99–102.
64.
Raphael C, Hudson E, Williams L, Lester JF, Savage PM. Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report. J Med Case Rep. 2010;4:413.PubMedPubMedCentralCrossRef
65.
Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Ichikawa Y. Sorafenib Monotherapy in a patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Rep Oncol. 2016;9(1):134–7.PubMedPubMedCentralCrossRef
66.
Pallotti MC, Nannini M, Agostinelli C, Leoni S, Scioscio VD, Mandrioli A, et al. Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World J Gastroenterol. 2014;20(22):7049–54.PubMedPubMedCentralCrossRef
67.
Bally O, Tassy L, Richioud B, Decouvelaere AV, Blay JY, Derbel O. Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. Clin Sarcoma Res. 2015;5:12.PubMedPubMedCentralCrossRef
68.
Kounis I, Lewin M, Laurent-Bellue A, Poli E, Coilly A, Duclos-Vallée JC, et al. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol. 2022;14:17588359221086909.PubMedPubMedCentralCrossRef
69.
Saada E, Saint Paul MC, Gugenheim J, Follana P, François E. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. Oncol Res Treat. 2014;37(3):124–6.PubMedCrossRef
70.
Telli TA, Okten IN, Tuylu TB, Demircan NC, Arikan R, Alan O, et al. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: a case series with review of the literature. Curr Probl Cancer. 2020;44(5):100568.PubMedCrossRef
71.
72.
Kayler LK, Merion RM, Arenas JD, Magee JC, Campbell DA, Rudich SM, et al. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation. 2002;74(1):128–30.PubMedCrossRef
73.
Liu XL, Yang ZY. Outcomes of hepatic epithelioid hemangioendothelioma with different managements: a retrospective investigation. Eur Rev Med Pharmacol Sci. 2021;25(12):4274–82.PubMed
74.
Liu X, Zhang Z, Huang J, Tan H, Yang Z. Efficacy and safety of Interferon-Alpha 2b for patients with hepatic epithelioid hemangioendothelioma: outcomes of a case-series analysis. Cancer Manag Res. 2021;13:8273–9.PubMedPubMedCentralCrossRef
75.
Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004;45(7):2056–64.PubMedCrossRef
76.
Cao B, Chen XP, Zhu P, Ding L, Guan J, Shi ZL. Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. World J Gastroenterol. 2008;14(44):6802–7.PubMedPubMedCentralCrossRef
77.
Quiroga AD, Vera MC, Ferretti AC, Lucci A, Comanzo CG, Lambertucci F, et al. IFN-α-2b induces apoptosis by decreasing cellular cholesterol levels in rat preneoplastic hepatocytes. Cytokine. 2020;133:155172.PubMedCrossRef
78.
Engel ER, Cournoyer E, Adams DM, Stapleton S. A retrospective review of the Use of Sirolimus for Pediatric patients with Epithelioid Hemangioendothelioma. J Pediatr Hematol Oncol. 2020;42(8):e826–9.PubMedCrossRef
79.
Cournoyer E, Al-Ibraheemi A, Engel E, Chaudry G, Stapleton S, Adams DM. Clinical characterization and long-term outcomes in pediatric epithelioid hemangioendothelioma. Pediatr Blood Cancer. 2020;67(2):e28045.PubMedCrossRef
80.
Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, et al. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: a case-series analysis within the Italian Rare Cancer Network. Cancer. 2021;127(4):569–76.PubMedCrossRef
81.
82.
Metadata
Title
The challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor
Authors
Manar Mikhail Atyah
Yongliang Sun
Zhiying Yang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03354-z

Other articles of this Issue 1/2024

The characteristics of eating, drinking and oro-pharyngeal swallowing difficulties associated with repaired oesophageal atresia/tracheo-oesophageal fistula: a systematic review and meta-proportional analysis

Genetic landscape of primary mitochondrial diseases in children and adults using molecular genetics and genomic investigations of mitochondrial and nuclear genome

  • Open Access
  • Research

Dysregulation of extracellular matrix and Lysyl Oxidase in Ehlers-Danlos syndrome type IV skin fibroblasts

Demographic characteristics, diagnostic challenges, treatment patterns, and caregiver burden of mitochondrial diseases: a retrospective cross-sectional study

  • Open Access
  • Research

An estimation of global genetic prevalence of PLA2G6-associated neurodegeneration

Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus